Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang  Is a corresponding author
  9. Zhiguang Yuchi  Is a corresponding author
  1. Tianjin University, China
  2. Chinese Academy of Sciences, China
  3. University of British Columbia, Canada

Abstract

Several mutations identified in phospholamban (PLN) have been linked to familial dilated cardiomyopathy (DCM) and heart failure, yet the underlying molecular mechanism remains controversial. PLN interacts with sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and regulates calcium uptake, which is modulated by the protein kinase A (PKA)-dependent phosphorylation of PLN during the fight-or-flight response. Here, we present the crystal structures of the catalytic domain of mouse PKA in complex with wild-type and DCM-mutant PLNs. Our structures, combined with the results from other biophysical and biochemical assays, reveal a common disease mechanism: the mutations in PLN reduce its phosphorylation level by changing its conformation and weakening its interactions with PKA. In addition, we demonstrate that another more ubiquitous SERCA-regulatory peptide, called another-regulin (ALN), shares a similar mechanism mediated by PKA in regulating SERCA activity.

Data availability

Diffraction data have been deposited in PDB under the accession code: PKAc-WT PLN (PDB 7E0Z); PKAc-PLN R9C (PDB 7E11); PKAc-PLN A11E (PDB 7E12).

The following data sets were generated

Article and author information

Author details

  1. Juan Qin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Jingfeng Zhang

    Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Lianyun Lin

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Omid Haji-Ghassemi

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Zhi Lin

    School of Life Sciences, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Kenneth J Woycechowsky

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Filip Van Petegem

    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Yan Zhang

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yan.zhang@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
  9. Zhiguang Yuchi

    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
    For correspondence
    yuchi@tju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2595-9106

Funding

National Natural Science Foundation of China (32022073)

  • Zhiguang Yuchi

National Natural Science Foundation of China (31972287)

  • Zhiguang Yuchi

Natural Science Foundation of Tianjin City (19JCYBJC24500)

  • Zhiguang Yuchi

Canadian Institutes of Health Research (PJT-159601)

  • Filip Van Petegem

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Qin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,996
    views
  • 297
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Juan Qin
  2. Jingfeng Zhang
  3. Lianyun Lin
  4. Omid Haji-Ghassemi
  5. Zhi Lin
  6. Kenneth J Woycechowsky
  7. Filip Van Petegem
  8. Yan Zhang
  9. Zhiguang Yuchi
(2022)
Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
eLife 11:e75346.
https://doi.org/10.7554/eLife.75346

Share this article

https://doi.org/10.7554/eLife.75346

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Jiale Zhou, Ding Zhao ... Zhanjun Li
    Research Article

    5-Methylcytosine (m5C) is one of the posttranscriptional modifications in mRNA and is involved in the pathogenesis of various diseases. However, the capacity of existing assays for accurately and comprehensively transcriptome-wide m5C mapping still needs improvement. Here, we develop a detection method named DRAM (deaminase and reader protein assisted RNA methylation analysis), in which deaminases (APOBEC1 and TadA-8e) are fused with m5C reader proteins (ALYREF and YBX1) to identify the m5C sites through deamination events neighboring the methylation sites. This antibody-free and bisulfite-free approach provides transcriptome-wide editing regions which are highly overlapped with the publicly available bisulfite-sequencing (BS-seq) datasets and allows for a more stable and comprehensive identification of the m5C loci. In addition, DRAM system even supports ultralow input RNA (10 ng). We anticipate that the DRAM system could pave the way for uncovering further biological functions of m5C modifications.